Assays for monitoring cellular immune responses to active immunotherapy of cancer.
Publication/Presentation Date
5-1-2001
Abstract
Numerous cancer immunotherapy strategies are currently being tested in clinical trials. Although clinical efficacy will be the final test of these approaches, the long and complicated developmental pathway for these agents necessitates evaluating immunological responses as intermediate markers of the most likely candidates for success. This has emphasized the need for assays that accurately detect and quantitate T cell-mediated, antigen-specific immune responses. This review evaluates the currently used in vivo and in vitro methods of assessing T-cell number and function, including delayed-type hypersensitivity, tetramer analysis, ELISPOT, flow cytometry-based analysis of cytokine expression, and PCR-based detection of T-cell receptor gene usage or cytokine production. We provide examples of how each has been used to monitor recent clinical trials and a discussion of how well each correlates with clinical outcome.
Volume
7
Issue
5
First Page
1127
Last Page
1135
ISSN
1078-0432
Published In/Presented At
Clay, T. M., Hobeika, A. C., Mosca, P. J., Lyerly, H. K., & Morse, M. A. (2001). Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 7(5), 1127–1135.
Disciplines
Medicine and Health Sciences
PubMedID
11350875
Department(s)
Department of Medicine
Document Type
Article